Celyad Oncology Reports First Half 2024 Financial Results and Recent Business Highlights

Regulatory News:

Celyad Oncology (Euronext: CYAD) (the “Company”) today announces financial results for the first half of 2024 ended June 30, 2024, and provides a business update.

Michel Lussier, Interim Chief Executive Officer of Celyad Oncology, commented: “Celyad Oncology continues to make remarkable progress in the development of advanced chimeric antigen receptor (CAR) T-cell therapy technologies. Our breakthrough multiplex platform revolutionizes the potential of CAR T cells, while our breakthrough NKG2D-based multi-specific CAR T cell platform further paves the way to overcome the current limitations of this transformative class of immunotherapy.”